Xoma Royalty CORP 8-K filings

Ligand Pharmaceuticals Incorporated has finalized its acquisition of XOMA Royalty Corporation, with XOMA Royalty stockholders receiving $39.00 per share in cash and a Contingent Value Right.

XOMA Royalty Corporation expects its acquisition by Ligand Pharmaceuticals to close on July 14, 2026, and has initiated the full redemption of its outstanding preferred stock.

XOMA Royalty Corp stockholders approved new equity incentive plans and the board adopted bylaw amendments regarding forum selection and Nevada statutes.

Xoma Royalty Corporation announced an amendment to its merger agreement with Ligand Pharmaceuticals Incorporated, adding a new holding company as a party to the transaction.

XOMA Royalty Corporation has finalized its acquisition of Generation Bio Co., integrating its assets and contingent value rights.

Ligand Pharmaceuticals announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash, aiming to expand its royalty portfolio and accelerate profit growth.

XOMA Royalty Corporation released an updated corporate presentation detailing its Q1 2026 strategy, preliminary FY2025 financial results, and key portfolio events anticipated in 2026.

XOMA Royalty Corporation has successfully completed its acquisition of Generation Bio Co., integrating the biotech firm and its assets, including contingent value rights for former shareholders.

XOMA Royalty Corporation finalized its acquisition of LAVA Therapeutics, outlining the future of acquired legacy assets and contingent value rights.

XOMA Royalty Corporation announced the appointment of Jeffrey Trigilio as its new Chief Financial Officer, succeeding Thomas Burns, effective January 12, 2026.

XOMA Royalty Corporation released an updated corporate presentation detailing its differentiated strategy as a biotech royalty aggregator and outlining key 2026 milestones.

XOMA Royalty Corporation has successfully completed its acquisition of Mural Oncology plc for $2.035 per share in cash, effective December 5, 2025.

XOMA Royalty Corporation announced the completion of its tender offer and acquisition of LAVA Therapeutics N.V., including a Post-Offer Reorganization.

XOMA Royalty Corporation announced robust third-quarter and year-to-date 2025 financial results, driven by increased royalty receipts and strategic acquisitions, while highlighting key pipeline advancements.

XOMA Royalty Corporation has established two at-the-market equity offerings, totaling up to $125 million, for common and preferred stock to fund acquisitions and general corporate purposes.

XOMA Royalty Corporation filed a Certificate of Correction to fix a typographical error in the Certificate of Designation for its 8.375% Series B Cumulative Perpetual Preferred Stock.

XOMA Royalty Corporation has successfully acquired HilleVax, Inc. through a tender offer and subsequent merger, providing HilleVax shareholders with $1.95 cash per share and a contingent value right.

XOMA Royalty Corporation has successfully completed its tender offer and subsequent merger with Turnstone Biologics Corp., acquiring all outstanding shares for cash and contingent value rights.

XOMA Royalty Corporation announced robust second quarter and year-to-date 2025 financial results, driven by increased royalty and milestone receipts, alongside strategic acquisitions and pipeline advancements.

XOMA Royalty Corporation announced the successful reincorporation from Delaware to Nevada and the approval of an amended long-term incentive plan and all director nominees at its recently concluded Annual Meeting of Stockholders.

XOMA Royalty Corporation reports a net income of $2.4 million for Q1 2025, driven by pipeline advancements and strategic acquisitions.

XOMA Royalty Corporation reports its Q4 and full year 2024 financial results, highlighting a doubled royalty and milestone portfolio and FDA approvals for OJEMDA and MIPLYFFA.

XOMA Royalty Corporation files an amendment to its original Form 8-K to include historical financial statements of Pulmokine, Inc., following its acquisition for $20 million.

XOMA Royalty Corporation has acquired Pulmokine, Inc. for $20 million in cash, gaining an economic interest in the Phase 3 asset seralutinib, which is being developed for pulmonary arterial hypertension.

XOMA Royalty Corporation announced its third quarter 2024 financial results, highlighted by the FDA approval of MIPLYFFA and a significant acquisition of early-stage assets from Twist Bioscience.

XOMA Royalty Corporation has acquired a 50% stake in future milestones and royalties from over 60 early-stage programs of Twist Bioscience for $15 million.

XOMA Royalty Corporation's portfolio expands with the FDA approval of Zevra Therapeutics' MIPLYFFA for Niemann-Pick disease type C, marking their sixth commercial asset.

XOMA Royalty Corporation announced a profitable second quarter of 2024, driven by key milestones, strategic acquisitions, and increased royalty income.

XOMA Corporation has officially changed its name to XOMA Royalty Corporation, effective July 10, 2024.

XOMA Corporation has filed an amendment to its original 8-K report to include historical financial statements of Kinnate Biopharma and pro forma financial information following the completion of its acquisition of Kinnate.